Jan 30, 2020 / NTS GMT
Hiroshi Nomura - Sumitomo Dainippon Pharma Co., Ltd. - CEO, President & Representative Director
This is Nomura, President and CEO of the company. Thank you very much for taking your time to listen to our presentation.
First of all, as announced on the press release, Sumitomo Dainippon Pharma completed the procedure for the formation of the strategic alliance with Roivant as of December 27, 2019. Today, we will be presenting the financial results for our quarter. And the impact by the alliance was reflected not on P&L, but on the balance sheet and the cash flow statement. The value of acquired assets and assumed liabilities on the balance sheet is provisional since the fair value evaluation has not completed yet, and the provisional figures and adjustments are being recorded as goodwill. We are expecting to present the results of ongoing fair valuation at the end of the fiscal year. Impact on our forecast on P&L will be presented later by Mr. Kashima.
Given the timing of the completion of the formation of the alliance with Roivant, I am expecting many questions on this matter to
Q3 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
Jan 30, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers